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We present a history of 76-year-old female with 
haematuria, hypertension, headaches, and excessive 
sweating. Urine cytology revealed atypical cells. Con-
trast-enhanced CT showed a 4 cm lesion of the urinary 
bladder. MRI and subsequent cystoscopy confirmed 
the presence of a tumour on the anterior wall of the 
urinary bladder. Endoscopic partial cystectomy was 
performed. Histopathological examination confirmed 
paraganglioma (positive staining for neuroendocrine 
neoplasm markers, negative staining for keratins, Ki-67 
— 15–20%). Repeated radical surgery (cystectomy) was 
not performed because of the patient’s refusal; she was 
lost for further observation and management for several 
months. One year after initial diagnosis, the patient was 
referred to the Endocrinology Department. A 24-hour 
urine collection of metoxycatecholamines showed sig-
nificantly elevated level of normetanephrine and 3-me-
toxythyramine (Tab. 1). Alpha-blocker treatment was 
initiated. Genetic testing for the major pheochromo-
cytoma/paraganglioma (PCC/PGL) susceptibility genes 
(SDH-B, -D, VHL, and RET) was negative. Control CT 
scan of the abdomen and pelvis identified, apart from 
primary tumour, suspicious paraaortic and right iliac 
lymph nodes. 131I-metaiodobenzylguanidine (MIBG) 
SPECT/CT showed no tracer uptake (Fig. 1), whereas 
68Ga-DOTATATE PET/CT identified pathological (Kern-
ing score 4) somatostatin receptor expression in urinary 
bladder mass, thoracic, abdominal, and pelvic lymph 
nodes (Fig. 2). Based on those results, the diagnosis of 
malignant, disseminated paraganglioma was made.
The patient, who still refused any kind of surgery, 
was referred to peptide receptor radionuclide therapy 
(PRRT) with the use of 177Luthetium (Lu)-DOTATATE. The 
treatment tolerance was good without clinically relevant 
adverse events. However, follow-up CT scan done after 
the third of the planned four treatment cycles showed 
the disease progression, resulting in cessation of the treat-
ment (Fig. 3). Because of very rapid progression of the 
disease, one of the pathological, supraclavicular lymph 
nodes was excised for histopathological assessment — the 
results showed progression of Ki-67 to 42%. At the time 
of reporting, the patient has remained in good clinical 
condition and she has been qualified for chemotherapy.
Paragangliomas (PGL) are rare tumours of neuroendo-
crine origin. Those localised in urinary bladder account for 
10% of all PGLs. Approximately 10% of them are malig-
nant. The common symptoms of the disease are haema-
table 1. Results of 24-hour urine collection of metoxyca-
techolamines
Normetanephrine 3311.5 ug/24 h (URL 440 ug/24 h)
3-metoxytyramine 1580 ug/24 h (URL 220 ug/24 h)
Metanephrine 62.7 ug/24 h (URL 341 ug/24 h)
URL — upper reference limit
Figure 1. 131I-metaiodobenzylguanidine (131I MIBG) SPECT/
/CT — no pathological tracer uptake
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of the disease was noted in approximately 20% of the 
patients [4]. Lately, it has been shown that longitudinal 
increase in Ki-67 index and tumour grade was a common 
feature of pancreatic neuroendocrine tumours, and it 
was linked to a poor outcome [5]. We speculate that, in 
our case, transformation of metastases to higher grade 
(with doubled Ki-67 index compared to primary lesion), 
confirmed in histopathological examination of the lymph 
node, could be the reason for PRRT treatment failure 
regardless of very good somatostatin receptor expression 
on baseline tumour cells.
Nevertheless, further research is needed for a bet-
ter understanding of the disease and response to the 
treatment.
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turia, which can be accompanied by hypertension, head-
ache, palpitation, and micturition syncope, as the result of 
oversecretion of catecholamines [1]. Unrevealed hormonal 
activity of paragangliomas, without alpha-blockage, can 
jeopardise patient safety due to possible catecholamine 
crisis. The tumour catecholamine profile can provide 
information about possible germline mutations since 
there is a strong genotype — phenotype correlation in 
these neoplasms [2]. However, 50% of metastatic PGLs 
are sporadic [3]. Treatment options for metastatic PGLs 
are limited — apart from palliative surgery, they include 
radiotherapy, chemotherapy, and PRRT [1]. Generally, 
disease stabilisation and improvement of symptoms by 
the use of surgery and adjuvant therapies is observed in 
less than 50% of patients with metastatic disease [1].
 The uptake of radiopharmaceuticals in metastatic 
PGLs depends on genetic background and differentia-
tion status of the tumour. 131I- MIBG treatment is reserved 
for patients with relevant tumour avidity to 123/131I-MIBG. 
Nonetheless, in metastatic PGLs 123/131I-MIBG tracer 
uptake is very often faint or even absent. Histopatho-
logically, the lack of keratin expression in a presumed 
neuroendocrine neoplasm (NEN) should raise the suspi-
cion of PGL [1, 2]. Histopathological distinction between 
PGL and NEN is very important because of the ability to 
overexpress somatostatin receptor 2 (SSR 2) presented by 
paragangliomas, which can lead to misdiagnosis when 
it is based on somatostatin receptor scintigraphy. Con-
versely, this ability enables 68Ga-DOTATATE PET/CT and 
PRRT use in the diagnosis and treatment of metastatic 
PGLs. Recent data of patients with sporadic and SDHB 
positive metastatic PGLs demonstrated the superiority of 
68Ga-DOTATATE PET/CT in the detection of metastases 
over 18F-FDG PET/CT, which is still recommended in the 
diagnosis of metastatic PGLs [2, 3].
Preliminary experience in the use of PRRT for surgi-
cally incurable PGLs suggests its low toxicity and favour-
able efficacy in disease control. However, progression 
Figure 2. 68Ga-DOTATATE — pathological somatostatin receptor 
expression in thoracic, abdominal, and pelvic lymph nodes (arrows)
Figure 3. Follow-up computed tomography of the thorax, abdomen, 
and pelvis done after the third PRRT cycle revealed significant 
progression of paraaortic thoracic, abdominal, and pelvic lymph 
node metastases (arrows)
